Goldman Sachs and Morgan Stanley are advising BD’s acquisition of Edwards Lifesciences’ Critical Care Product Group for $4.2 billion.
![Goldman Sachs signage at the New York Stock Exchange. PHOTO: Corbis/Getty images](https://krugmaninsights.com/wp-content/uploads/2023/12/file_usa_economy_goldman_sachs-1024x682.webp)
This move enhances BD’s portfolio with advanced patient monitoring technologies and AI-enabled clinical decision tools. BD, a global medical technology leader, has agreed to buy the Critical Care division from Edwards Lifesciences. Specializing in advanced monitoring solutions, this division includes innovations like